Study ID

No. of patients

Follow-up time

Crizotinib dosage

Chemotheraputic drugs

Trials phase

Blind methods

Ethnicity

Shaw AT, 2013 [7]

347

12 mo

250 mg, twice daily

pemetrexed, docetaxel

3

×

Multi-races

Solomon BJ, 2014 [8]

343

-

250 mg, twice daily

pemetrexed, carboplatin

3

×

Multi-races

NCT01639001, 2017 [9]

207

-

250 mg, twice daily

pemetrexed, carboplatin, cisplatin

3

√

Asian

Zhu LY, 2016 [10]

86

12 mo

250 mg, twice daily

pemetrexed, docetaxelgemcitabine, carboplatin

4

×

Asian

Wu RH, 2017 [11]

50

12 mo

250 mg, twice daily

docetaxel

4

√

Asian

Zhao J, 2015 [12]

28

12 mo

250 mg, twice daily

docetaxel

4

×

Asian

Ding WB, 2017 [13]

60

-

250 mg, twice daily

docetaxel

4

×

Asian